Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 358 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Urinary Bladder Overactive Clear all
Not listed Phase 4 Interventional Accepts healthy volunteers

Premarin Versus Toviaz for Treatment of Overactive Bladder

NCT01613170
View directory record Official record
Conditions
Overactive Bladder
Interventions
Toviaz, Premarin, Placebo cream
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
30 Years to 100 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Jul 22, 2026, 5:02 PM EDT
Withdrawn Not applicable Interventional

Neuromodulation Implantation Settings Variation for Overactive Bladder

NCT02112786
View directory record Official record
Conditions
Overactive Bladder
Interventions
Intermittent or Continuous Setting RestorePrime Implanted Impulse Generator
Device
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Jul 22, 2026, 5:02 PM EDT
Not listed Phase 4 Interventional

Oral vs Intravesical Analgesia for Office Bladder Botox Injections

NCT03755089
View directory record Official record
Conditions
Overactive Bladder Syndrome, Urge Incontinence, Urinary Incontinence, Detrusor Hyperreflexia, Detrusor Instability
Interventions
Phenazopyridine, Lidocaine 2% Injectable Solution
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Jul 22, 2026, 5:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects

NCT00703703
View directory record Official record
Conditions
Healthy
Interventions
Darifenacin, Tolterodine, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
21
States / cities
Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Jul 22, 2026, 5:02 PM EDT
Not yet recruiting Not applicable Interventional

Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy

NCT07662824
View directory record Official record
Conditions
Cervical Carcinoma, Endometrial Carcinoma, Overactive Bladder, Voiding Disorders
Interventions
Educational Intervention, Interview, Flyte Medical Device Usage and Evaluation, Questionnaire Administration, Referral
Other · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 22, 2026, 5:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects

NCT00911235
View directory record Official record
Conditions
Overactive Bladder With Symptoms of Frequency, Urgency, and Urge Urinary Incontinence
Interventions
Fesoterodine, fesoterodine plus fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 31, 2011 · Synced Jul 22, 2026, 5:02 PM EDT
Completed Phase 4 Interventional

Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder

NCT00171184
View directory record Official record
Conditions
Overactive Bladder
Interventions
Darifenacin, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
65 Years and older
Enrollment
400 participants
Timeline
2005 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Jul 22, 2026, 5:02 PM EDT
Terminated Phase 4 Interventional Results available

Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate

NCT01605617
View directory record Official record
Conditions
Overactive Bladder
Interventions
Fesoterodine fumarate, Placebo, Percutaneous Tibial Nerve Stimulation (PTNS)
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Jul 22, 2026, 5:02 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Caffeine Reduction and Overactive Bladder Symptoms

NCT00754260
View directory record Official record
Conditions
Overactive Bladder
Interventions
Caffeine reduction
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Jul 22, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

NCT00611026
View directory record Official record
Conditions
Overactive Bladder
Interventions
Tolterodine ER, Placebo, Fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
102
States / cities
Enterprise, Alabama • Mobile, Alabama • Montgomery, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2011 · Synced Jul 22, 2026, 5:02 PM EDT
Completed Phase 4 Interventional Results available

Validation of a Real-time Urodynamic Measure of Urinary Urgency

NCT00909428
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Solifenacin Succinate
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Jul 22, 2026, 5:02 PM EDT
Active, not recruiting Not applicable Interventional

Trial for Reliability of Urodynamics SysTem

NCT05694793
View directory record Official record
Conditions
Urologic Diseases, Urodynamics
Interventions
Glean Urodynamics System
Device
Lead sponsor
Bright Uro
Industry
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Murrieta, California • San Diego, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 22, 2026, 5:02 PM EDT
Terminated Not applicable Interventional

Overactive Bladder Education

NCT02505607
View directory record Official record
Conditions
Urinary Bladder, Overactive, Urinary Incontinence, Urge
Interventions
Overactive Bladder Care Plan counseling
Other
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
Glastonbury, Connecticut • Hartford, Connecticut • West Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Jul 22, 2026, 5:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Botulin-A Toxin Instillations and Overactive Bladder

NCT00583219
View directory record Official record
Conditions
Overactive Bladder, Detrusor Instability, Detrusor Hyperreflexia
Interventions
Botulinum-A toxin, Dimethyl sulfoxide (DMSO)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jul 22, 2026, 5:02 PM EDT
Not listed Phase 3 Interventional

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER

NCT01050114
View directory record Official record
Conditions
Overactive Bladder
Interventions
onaBoNT-A, Oxybutynin ER
Drug
Lead sponsor
Christopher Patrick Smith
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Jul 22, 2026, 5:02 PM EDT
Completed Phase 1 Interventional

Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function

NCT04454424
View directory record Official record
Conditions
Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions
BAY1817080, Midazolam
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Jul 22, 2026, 5:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Animated Videos to Foster Healthy Bladder Behaviors in Community Women

NCT06921915
View directory record Official record
Conditions
Urinary Bladder, Overactive, Urinary Incontinence, Urge
Interventions
eLearning
Other
Lead sponsor
Kathleen O'Connell
Other
Eligibility
40 Years to 64 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Jul 22, 2026, 5:02 PM EDT
Completed Not applicable Interventional

Usability Study of the FemPulse System

NCT06347380
View directory record Official record
Conditions
Overactive Bladder
Interventions
FemPulse System
Device
Lead sponsor
FemPulse Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Fort Lauderdale, Florida • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 22, 2026, 5:02 PM EDT
Completed Phase 4 Interventional

Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction

NCT00147654
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Tolterodine ER 4 mg QD, Tamsulosin 0.4 mg QD
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
95
States / cities
Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Jul 22, 2026, 5:02 PM EDT
Not listed Phase 2Phase 3 Interventional

This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.

NCT00479596
View directory record Official record
Conditions
Overactive Bladder
Interventions
Botox
Drug
Lead sponsor
Urological Sciences Research Foundation
Other
Eligibility
40 Years to 90 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated May 29, 2007 · Synced Jul 22, 2026, 5:02 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Oxybutynin and Omega-3 for OAB (Overactive Bladder)

NCT02070042
View directory record Official record
Conditions
Overactive Bladder
Interventions
Omega 3 Fatty Acid, Placebo
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Jul 22, 2026, 5:02 PM EDT
Completed No phase listed Observational

Overactive Bladder (OAB) Voiding Diary and Urodynamics Correlation Study

NCT03473782
View directory record Official record
Conditions
Overactive Bladder
Interventions
Voiding Diary, Urodynamics Correlation Study
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 110 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Jul 22, 2026, 5:02 PM EDT
Terminated No phase listed Observational

PTNS vs Botox of Refractory OAB

NCT04451382
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
OnabotulinumtoxinA (BoNTA), Percutaneous tibial nerve stimulation (PTNS)
Biological · Procedure
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Jul 22, 2026, 5:02 PM EDT
Completed Not applicable Interventional

FemPulse Therapy for Overactive Bladder in Women

NCT03784170
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
FemPulse System
Device
Lead sponsor
FemPulse Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Woodbury, Minnesota • Charlotte, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 22, 2026, 5:02 PM EDT